Abstract | BACKGROUND AND OBJECTIVES: METHODS: The pharmacokinetics of ABT-806 were evaluated in a phase I, open-label study in cancer patients following intravenous infusion of ABT-806 every other week. A total of 587 serum concentrations of ABT-806 from 61 patients were analyzed using non-linear mixed-effects modeling. The impact of body weight-based and fixed dosing of ABT-806 was evaluated using a simulation approach. RESULTS: A two-compartment model with linear elimination was used to describe the serum concentration-time data of ABT-806. The population estimates of the apparent clearance from the central (CLc) and peripheral (CLp) compartments were 0.011 and 0.025 L/h, respectively. The apparent volume of distribution estimates of the central (V 1) and peripheral (V 2) compartments were 3.5 and 3.3 L, respectively. The estimates of inter-subject variability (percentage coefficient of variation) in CLc, CLp, V 1, and V 2 were 38, 37, 20, and 48 %, respectively. Albumin on CLc and body weight on V 1 were statistically significant covariates; however, they explained 18 and 30 % of the inter-individual variability of clearance and V 1, respectively. Simulation results indicated that fixed and body weight-based dosing regimens yield similar steady-state concentrations and overall variability. CONCLUSIONS:
ABT-806 demonstrated a unique pharmacokinetic profile compared to the marketed monoclonal antibodies against EGFR. The analysis indicates it is feasible to switch to fixed doses in subsequent clinical trials of ABT-806.
|
Authors | Shringi Sharma, Rajendar K Mittapalli, Kyle D Holen, Hao Xiong |
Journal | Clinical pharmacokinetics
(Clin Pharmacokinet)
Vol. 54
Issue 10
Pg. 1071-81
(Oct 2015)
ISSN: 1179-1926 [Electronic] Switzerland |
PMID | 25761639
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- epidermal growth factor receptor VIII
- EGFR protein, human
- ErbB Receptors
- depatuxizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(administration & dosage, blood, immunology, pharmacokinetics)
- Body Weight
- Dose-Response Relationship, Drug
- ErbB Receptors
(antagonists & inhibitors, genetics, immunology)
- Female
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Neoplasms
(blood, drug therapy, genetics, metabolism)
|